Trouble Getting Weight Loss Drugs Covered by Insurance? Here’s What To Know
If your doctor prescribes a GLP-1 medication for weight loss but your insurance won’t cover it, you have options.
Obesity
1 - 20 of 97 Results
-
-
Telehealth Booms as Demand for GLP-1s Surges and Questions Mount About Safety, Oversight
Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded. Meanwhile, researchers and doctors are concerned that some of these online companies aren't properly screening or monitoring patients. “It gives a black eye to telemedicine,” one researcher said.
By Lauren Sausser and Maia Rosenfeld -
Trump Bought Stock in Eli Lilly as His Policies Gave the Drugmaker a Big Boost, Documents Show
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.
By Darius Tahir -
A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
It may soon get easier for millions of people with Medicare to get discounted GLP-1 drugs for weight loss.
-
The New Old Age
Older Americans Quit Weight Loss Drugs in Droves
In some studies, half of patients stopped taking GLP-1s within a year despite the benefits, citing the expense and side effects.
By Paula Span -
In Mississippi, Medicaid Coverage of Weight Loss Drugs Fails To Catch On
In Mississippi, a state with one of the highest obesity rates in the nation, Medicaid covers weight loss drugs, but few enrollees have signed up for the benefit.
-
As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off
Conventional wisdom says GLP-1 drugs must be taken indefinitely to maintain weight loss. But a growing number of researchers, payers, and providers are challenging that consensus and exploring whether — and how — to taper patients off expensive GLP-1 drugs.
-
Chronically Ill? In Kennedy’s View, It Might Be Your Own Fault
In their zeal to “Make America Healthy Again,” top Trump administration officials depict patients and the doctors who treat them as partly responsible for whatever ails them.
-
A Revolutionary Drug for Extreme Hunger Offers Clues to Obesity’s Complexity
A new drug is helping families who’ve spent years padlocking fridges, chaining garbage cans, and hiding food as their children with Prader-Willi syndrome deal with unrelenting hunger. But additional progress — and a broader understanding of obesity — is now under threat as the government dismantles the pipeline for promising new research.
-
Trump Won’t Force Medicaid To Cover GLP-1s for Obesity. A Few States Are Doing It Anyway.
Late last year, South Carolina Medicaid approved a class of medications known as GLP-1s to treat obesity, placing it among the few state programs covering these effective but expensive drugs. But access remains limited, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.
-
Junk Food Turns Public Villain as Power Shifts in Washington
Some Trump insiders are ready to take on the food industry. It remains to be seen whether their entrée will result in any meaningful change in government oversight of “Big Food” — or in American health.
By Stephanie Armour and David Hilzenrath -
Journalists Dig Into Vaccine Debate and America’s Obesity Rates
KFF Health News staff made the rounds on national and local media in recent weeks to discuss topical stories. Here’s a collection of their appearances.
-
Journalists Talk Obesity, Oximeters, and Severe Weather’s Impact on Public Health
KFF Health News and California Healthline staff made the rounds on national and local media in recent weeks to discuss topical stories. Here’s a collection of their appearances.
-
How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices
As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”
By Arthur Allen -
-
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
By Arthur Allen -
-
Journalists Talk Cost of Weight Loss Drugs and Lack of Obesity Doctors to Manage Their Use
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss topical stories. Here’s a collection of their appearances.
-
High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
-
Arkansas Led the Nation in Measuring Obesity in Kids. Did It Help?
For more than 20 years, children in Arkansas have been measured in school as part of a statewide effort to reduce childhood obesity. But the letters have had no impact on weight loss — and obesity rates have risen. Still, the practice of sending letters has spread to other states.